Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The role of vasodilators in the prevention and treatment of no-reflow following percutaneous coronary intervention.

Literature DB >> 16606861

The role of vasodilators in the prevention and treatment of no-reflow following percutaneous coronary intervention.

Abstract

The routine use of vasodilators in patients with acute coronary syndromes or other groups undergoing percutaneous coronary intervention (PCI) cannot be recommended at present. However, in the event of no-reflow occurring following PCI, intracoronary adenosine or verapamil should be administered.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2006 PMID： 16606861 PMCID： PMC1861163 DOI： 10.1136/hrt.2006.088427

Source DB: PubMed Journal: Heart ISSN： 1355-6037 Impact factor: 5.994

16 in total

Review 1. The coronary no-reflow phenomenon: a review of mechanisms and therapies.

Authors: E Eeckhout; M J Kern
Journal: Eur Heart J Date: 2001-05 Impact factor: 29.983

2. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction.

Authors: Y Taniyama; H Ito; K Iwakura; T Masuyama; M Hori; S Takiuchi; N Nishikawa; Y Higashino; K Fujii; T Minamino
Journal: J Am Coll Cardiol Date: 1997-11-01 Impact factor: 24.094

3. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction.

Authors: M Marzilli; E Orsini; P Marraccini; R Testa
Journal: Circulation Date: 2000-05-09 Impact factor: 29.690

4. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial.

Authors: K W Mahaffey; J A Puma; N A Barbagelata; M F DiCarli; M A Leesar; K F Browne; P R Eisenberg; R Bolli; A C Casas; V Molina-Viamonte; C Orlandi; R Blevins; R J Gibbons; R M Califf; C B Granger
Journal: J Am Coll Cardiol Date: 1999-11-15 Impact factor: 24.094

5. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II).

Authors: Allan M Ross; Raymond J Gibbons; Gregg W Stone; Robert A Kloner; R Wayne Alexander
Journal: J Am Coll Cardiol Date: 2005-06-07 Impact factor: 24.094

6. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction.

Authors: Gerald S Werner; Klaus Lang; Helmuth Kuehnert; Hans R Figulla
Journal: Catheter Cardiovasc Interv Date: 2002-12 Impact factor: 2.692

7. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial.

Authors: Andrew D Michaels; Mark Appleby; Matthew H Otten; Kent Dauterman; Thomas A Ports; Tony M Chou; C Michael Gibson
Journal: J Invasive Cardiol Date: 2002-06 Impact factor: 2.022

The role of vasodilators in the prevention and treatment of no-reflow following percutaneous coronary intervention.

Review 1. The coronary no-reflow phenomenon: a review of mechanisms and therapies.

2. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction.

3. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction.

4. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial.

5. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II).

6. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction.

7. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial.

8. Intense microvascular constriction after angioplasty of acute thrombotic coronary arterial lesions.

9. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention.

10. Features and outcome of no-reflow after percutaneous coronary intervention.

1. Intracoronary bivalirudin for no reflow reversal: a second chance to treat this disorder?

Review 2. No-Reflow Phoenomenon by Intracoronary Thrombus in Acute Myocardial Infarction.